26 years of historical data (1999–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inovio Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $50M | $136M | $372M | $12.9B | $18.0B | $4.9B | $4.4B | $4.1B | $6.1B | $5.5B |
| Enterprise Value | $11M | $-4243731 | $152M | $358M | $12.8B | $17.8B | $5.0B | $4.4B | $4.0B | $6.1B | $5.5B |
| P/E Ratio → | -0.46 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 300.07 | 228.26 | 163.10 | 36.27 | 7241.33 | 2434.12 | 1200.19 | 145.72 | 96.16 | 172.39 | 135.88 |
| P/B Ratio | 0.72 | 0.73 | 1.16 | 1.67 | 32.16 | 39.12 | 913.07 | 51.04 | 28.49 | 49.42 | 31.34 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -19.49 | 182.21 | 34.88 | 7219.85 | 2405.55 | 1218.99 | 144.95 | 95.60 | 171.85 | 134.46 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Inovio Pharmaceuticals, Inc. earns an operating margin of -51616.9%. Operating margins have compressed from -2607.4% to -51616.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -115.4% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -51616.9% | -51616.9% | -17300.3% | -2607.4% | -16972.3% | -1674.2% | -2702.1% | -308.7% | -198.1% | -215.5% | -84.5% |
| Net Profit Margin | -49254.3% | -49254.3% | -16239.9% | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% | -71.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -115.4% | -115.4% | -79.5% | -90.0% | -70.6% | -71.3% | -258.2% | -84.5% | -66.4% | -49.3% | -20.3% |
| ROA | -75.5% | -75.5% | -52.0% | -66.3% | -58.6% | -48.7% | -86.8% | -60.9% | -48.9% | -38.1% | -16.9% |
| ROIC | -114.1% | -114.1% | -63.3% | -70.5% | -73.9% | -56.0% | -114.1% | -77.5% | -56.3% | -51.4% | -27.2% |
| ROCE | -109.0% | -109.0% | -75.7% | -78.5% | -64.9% | -40.7% | -107.0% | -76.0% | -59.4% | -48.8% | -22.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $66M exceeds total debt of $12M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.26 | 0.14 | 0.08 | 0.08 | 18.41 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.79 | 0.14 | -0.06 | -0.10 | -0.46 | 14.30 | -0.27 | -0.17 | -0.16 | -0.33 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -632.05 | -632.05 | -117.71 | -213.38 | -155.55 | -14.26 | -13.98 | — | -3225.35 | -547.48 | — |
Net cash position: cash ($66M) exceeds total debt ($12M)
Short-term solvency ratios and asset-utilisation metrics
Inovio Pharmaceuticals, Inc.'s current ratio of 2.77x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.25x to 2.77x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.77 | 2.77 | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | 2.49 | 3.91 | 2.84 | 5.46 |
| Quick Ratio | 2.77 | 2.77 | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | 2.49 | 3.91 | 2.84 | 5.46 |
| Cash Ratio | 2.66 | 2.66 | 3.41 | 2.61 | 6.10 | 9.87 | 2.80 | 2.30 | 3.60 | 2.39 | 5.18 |
| Asset Turnover | — | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.03 | 0.23 | 0.23 | 0.20 | 0.19 |
| Inventory Turnover | 2.27 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 2009.84 | 1055.17 | 417.50 | 1651.88 | 938.88 | 180.38 | 48.56 | 56.11 | 171.00 | 65.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inovio Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $27M | $22M | $20M | $215M | $170M | $125M | $93M | $82M | $73M | $68M |
Compare INO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| INOYou | $65M | -0.5 | — | — | 100.0% | -51616.9% | -115.4% | -114.1% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| SCNI | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how INO stacks up against sector leader BioNTech SE.
Start ComparisonInovio Pharmaceuticals, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Inovio Pharmaceuticals, Inc.'s return on equity (ROE) is -115.4%. The historical average is -77.7%.
Based on historical data, Inovio Pharmaceuticals, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Inovio Pharmaceuticals, Inc. has 100.0% gross margin and -51616.9% operating margin.